Global Hereditary Cancer Testing Market projected to grow at 7.5% CAGR, reaching USD 12.1 billion by 2033.

From GlobeNewswire: 2024-04-02 14:00:00

Custom Market Insights has published a report on the global Hereditary Cancer Testing Market, projecting a compound annual growth rate (CAGR) of about 7.5% from 2024 to 2033. The market was valued at approximately USD 5.8 billion in 2023 and is expected to reach around USD 12.1 billion by 2033. Factors driving market growth include increasing awareness, technological advancements, rising incidence of hereditary cancers, expanding applications in precision medicine, government initiatives, growing demand for preventive healthcare, and expanding access to genetic counseling services. Partnerships and acquisitions in the market include MedGenome introducing a genetic test for Facioscapulohumeral Muscular Dystrophy diagnosis and Quest Diagnostics acquiring Blueprint Genetics for gene variant interpretation using next-generation sequencing. The report covers market size, growth factors, key segments, revenue estimation, competitive landscape, and recent trends, with regional scope across North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The COVID-19 pandemic impacted the market with disruptions in healthcare services, economic constraints, patient concerns, resumption of services, emphasis on telemedicine and remote testing, government support, and public health campaigns.

For more information and to access a free sample report of the Global Hereditary Cancer Testing Market, visit custommarketinsights.com.



Read more at GlobeNewswire: [Latest] Global Hereditary Cancer Testing Market Size/Share